Sunshine Lake Pharma Co Ltd
Company Profile
Business description
Sunshine Lake Pharma Co Ltd is a a vertically integrated pharmaceutical company engaging in research and development, production and commercialization of pharmaceutical products. It strategically focus on therapeutic areas of infectious diseases, chronic diseases and oncology. Its existing anti-infective product portfolio mainly includes (i) its top-selling product, Kewei (oseltamivir phosphate), for the treatment of influenza (in particular, Type A and Type B influenza viruses), (ii) one innovative drug developed in-house, Dongweien (emitasvir phosphate), for the treatment of hepatitis C, and (iii) three generic drugs for the treatment of infections caused by sensitive bacteria, namely Clarithromycin, Levofloxacin and Moxifloxacin Hydrochloride.
Contact
No. 368 Zhen An Zhong Road
HEC Scientific Park
Chang’an County
Guangdong Province
Dongguan
CHNT: +86 76985315888
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
6,550
Stocks News & Analysis
stocks
The best way to get rich and retire early
stocks
Investors too optimistic about ASX growth story
stocks
Stellar growth from ASX retailer but markets still too optimistic
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,111.70 | 38.60 | -0.42% |
| CAC 40 | 7,753.42 | 54.90 | 0.71% |
| DAX 40 | 24,024.78 | 56.56 | -0.23% |
| Dow JONES (US) | 44,458.61 | 483.52 | 1.10% |
| FTSE 100 | 9,147.81 | 18.10 | 0.20% |
| HKSE | 25,487.53 | 517.85 | 2.07% |
| NASDAQ | 21,681.90 | 296.50 | 1.39% |
| Nikkei 225 | 43,260.61 | 542.44 | 1.27% |
| NZX 50 Index | 12,766.54 | 6.86 | 0.05% |
| S&P 500 | 6,445.76 | 72.31 | 1.13% |
| S&P/ASX 200 | 8,836.60 | 44.20 | -0.50% |
| SSE Composite Index | 3,683.37 | 17.45 | 0.48% |